Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery

Launched by THE AFFILIATED NANJING DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL · Apr 7, 2024

Keywords

ClinConnect Summary

This clinical trial is studying whether a medication called liraglutide can help prevent delirium, which is a type of confusion, in older patients with Type 2 diabetes who are having cardiac surgery. Delirium can be a serious issue after surgery, especially for elderly patients, and this study aims to find out if liraglutide can reduce the chances of experiencing this condition after their operation.

To be eligible for the trial, participants need to be at least 60 years old, have Type 2 diabetes, and be scheduled for elective cardiac surgery. However, individuals with certain medical conditions, such as severe mental health issues or significant heart problems, cannot participate. If someone joins the study, they can expect to receive liraglutide around the time of their surgery and will be monitored for any changes in their mental state afterward. It's a great opportunity for eligible patients to contribute to important research that could improve care for others in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 60 years
• • 2. Type 2 diabetes
• • 3. Patients undergoing elective cardiac surgery
• Exclusion Criteria:
• • 1. History of neurological or psychiatric disorders, such as schizophrenia, epilepsy, Parkinson's disease, severe dementia, etc
• • 2. Patients with communication difficulties, such as severe visual, auditory, or speech impairments
• • 3. History of central nervous system damage or surgery
• • 4. Cardiac function NYHA Class IV
• • 5. Severe liver dysfunction (Child-Pugh Class C)
• • 6. Severe renal failure requiring renal replacement therapy
• • 7. History of pancreatitis
• • 8. Type 1 diabetes
• • 9. Patients whose blood sugar is difficult to control within 4-8 mmol/L during the screening period
• • 10. Patients with medullary thyroid carcinoma or a family history of it
• • 11. Pregnant or breastfeeding women
• • 12. Intolerance or allergy to liraglutide
• • 13. Previous use of GLP-1A and SGLT2i
• • 14. Patients who refuse to sign the informed consent